BI 409306
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
3
Sites
82
Countries
12
Endpoints
28
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 28 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 12 of 28 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
4
4
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02337907BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease. | BI 409306, Donepezil Alzheimer’s disease | Study partner/caregiver required | Ph 2 | Completed | 60 | Sep 2017 | 1 | results |
| NCT02240693Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo | BI 409306 Alzheimer’s disease | prodromal AD | Ph 2 | Completed | 52 | Sep 2017 | 1 | results |
| NCT02392468Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers | BI 409306 Alzheimer’s disease | mild AD dementia | Ph 1 | Completed | 3 | Aug 2017 | - | results |
Showing 1-3 of 3 trials